07Jul 2023
Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial

Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial

A study comparing three commonly used antiretroviral therapy (ART) regimens for HIV-1 during pregnancy and postpartum found that dolutegravir-based ART, particularly in combination with emtricitabine and tenofovir alafenamide, is safer and more effective than efavirenz-based ART. The research, conducted on 643 pregnant women in multiple countries, showed no significant differences in adverse events between the regimens, but a lower mortality rate in infants born to mothers on dolutegravir-based ART. At 50 weeks postpartum, the dolutegravir-containing groups showed comparable virological efficacy to the efavirenz-containing group. Overall, the study supports the recommendation of dolutegravir-based ART for pregnant women with HIV-1.

  • #gynaecology - ivf

Like

Save

Share